- ✓Automated insulin delivery systems brought nearly 3 in 4 French Type 1 diabetes patients to recommended blood sugar targets within 3 months — and those gains held for a full year.
| Country | France |
| Institution | Department of Diabetology and Endocrinology, Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris |
| Journal | Diabetes, obesity & metabolism |
| Year | 2026 |
| PMID | 41287199 |
France's Largest Real-World Insulin Pump Study Delivers Encouraging News for Type 1 Diabetes Patients
A study from France published in Diabetes, Obesity & Metabolism offers some of the strongest real-world evidence yet that automated insulin delivery (AID) systems — sometimes called "closed-loop" or "artificial pancreas" systems — work outside of carefully controlled clinical trials. Researchers at Lariboisière Hospital, part of the prestigious Assistance Publique-Hôpitaux de Paris network, tracked 2,741 adults and children with Type 1 diabetes across 79 centers nationwide over 12 months.
What Makes This Study Different from US Research?
Most AID studies in the United States have been conducted in controlled clinical trial settings, which don't always reflect everyday life. This French study is what researchers call an "observational" study — meaning it followed real patients in routine clinical care, not a curated trial group. France's centralized national healthcare system allowed researchers to collect consistent data across 79 clinics simultaneously, something that is logistically much harder to do in the fragmented US healthcare landscape. That makes these findings particularly meaningful for understanding how these devices perform in the real world.
What Did the Study Find?
After 12 months of using an AID system, patients saw significant improvements across every major measure:
- Time in Range (TIR) improved from 58% to 70%. TIR measures how many hours per day blood sugar stays in the healthy target zone of roughly 70–180 mg/dL. The American Diabetes Association (ADA) recommends a TIR of at least 70% for most Type 1 patients — this study's average landed right at that target.
- A1C dropped from 7.6% to 7.0%. This is a 3-month blood sugar average. The ADA recommends most Type 1 adults aim for below 7%, so patients in this study crossed that threshold by year's end.
- Severe hypoglycemia (dangerous low blood sugar) fell by 78% — from 4.1% of patients experiencing a severe episode to just 0.9%.
- Diabetic ketoacidosis (DKA) was cut nearly in half, from 1.2% to 0.6% of patients.
- Nearly all patients stayed on the devices. Only 2.8% discontinued use over 12 months — an unusually high adoption rate for any diabetes technology.
Critically, improvements appeared within the first 3 months and held steady through the full year — suggesting these aren't honeymoon-period results.
Does This Align With US Guidelines?
Yes, strongly. The ADA's Standards of Care recommend AID systems for most people with Type 1 diabetes who are willing to use them. This French nationwide data supports that recommendation with large-scale, real-world evidence. The two most common systems used — MiniMed 780G (49.7% of patients) and Tandem Control-IQ (49.3%) — are both FDA-approved and widely available in the United States.
Why This Matters for US Patients
If you or a loved one has Type 1 diabetes and is considering an AID system, this study provides reassurance that the benefits seen in clinical trials translate to everyday life. The dramatic reduction in severe hypoglycemic episodes is especially important — dangerous lows are one of the most feared complications of Type 1 diabetes and a leading reason patients and families hesitate to intensify insulin therapy. Whether you're newly diagnosed or have been managing Type 1 for decades (the average patient in this study had diabetes for 19 years), these devices showed consistent benefit.
Managing Type 1 diabetes with an AID system still requires high-quality glucose monitoring supplies and consistent care. Visit mdsdiabetes.com to explore CGM-compatible diabetes supplies that support your insulin delivery system and help you stay in range every day.
Citation
Riveline, Julla, Bonnemaison (2026). A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events. Diabetes, Obesity & Metabolism. PMID: 41287199. DOI: 10.1111/dom.70302. [France — Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris]